A single, 2 g/kg dose of immune globulin (IG), denoted 2 g-intravenous (IV)IG, has become a standard regimen for treating Kawasaki disease (KD) because of its highly preventive effect on coronary arterial lesions (CAL). However, IG is obtained from blood specimens, a drawback to many patients, and is also very expensive. This randomized prospective study reported here was carried out with the aim of developing a treatment regimen that would reduce the total dose of IG. The study tested two protocols (A: 2 g-IVIG; B: 1 g-IVIG) that included the strategy of administering additional IVIG to IVIG-resistant patients based on the criteria we described previously. In protocol A, an additional 2 g-IVIG was administered only once; in protocol B, the first additional IVIG was 1 g-IVIG and the second was 2 g-IVIG. One hundred and nine patients who were admitted before the seventh day of illness and had no CAL at the time of admission were enrolled in the study (protocol A: 54 patients; B: 55 patients). In the protocol A group, 7.4% (4/54) of the patients received 4 g/kg IG. In protocol B, 41.8% (23/55) were treated only with 1 g/kg IG, and 10.9% (6/55) received 4 g/kg IG. No significant differences were observed between the patients of the two subgroups receiving 4 g/kg IG in each protocol group. Discriminate analysis also suggested that 52.4% of the patients in the protocol A group could be treated only with 1 g/kg IG. On the other hand, no significant difference was observed in the incidence of aneurysms between patients in the protocol A group (1/54) and those in the protocol B group (4/55). Our protocol based on 1 g-IVIG, including additional IVIG, was assessed to be an effective treatment and to provide a considerably useful means to reduce the total dose of IG.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Coronary arterial lesions
Intravenous immune globulin
left coronary artery
right coronary artery
Fasano MB (1995) Risks and benefits of intravenous immunoglobulin treatment in children. Curr Opin Pediatr 7:688–694
Hashino K, Ishii M, Iemura M, Akagi T, Kato H (2001) Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43:211–217
Jibiki T, Terai M, Kurosaki T, Nakajima H, Suzuki K, Inomata H, Terashima I, Honda T, Yasukawa K, Hamada H, Kohno Y (2004) Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 163:229–233
Lang B, Duffy CM (2002) Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol 16:427–442
Lee MS, An SY, Jang GC and Kim DS (2002) A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate. Yonsei Med J 43:527–532
Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H (2004) Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 89:776–780
Mori M, Tomono N, Yokota S (1995) Coronary arteritis of Kawasaki disease unresponsive to high-dose intravenous gammaglobulin successfully treated with plasmapheresis. Nihon Rinsho Meneki Gakkai Kaishi 18:282–288
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639
Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS and Flynn I (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children (Cochrane Review). Cochrane Database Syst Rev 4: CD004000 (DOI 10.1002/14651858.CD004000)
Onouchi Z, Kawasaki T (1999) Overview of pharmacological treatment of Kawasaki disease. Drugs 58:813–822
Redwan EL (2002) Biochemical and immunological properties of four intravenous Immunoglobulin G preparations. Hum Antibodies 11:79–84
Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H (1999) Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Pediatr Int 41:1–7
Shulman ST, Rowley AH (2004) Advances in Kawasaki disease. Eur J Pediatr 163:285–291
Suto F, Sakata K, Kamiya Y, Hamaoka K, Onouchi Z, Tanaka T, Nukina S (1998) Additional gamma-globulin therapy (IVGG) for the patients of Kawasaki disease who are resistant to first IVGG. Prog Med 18:1649–1651
Suto F, Sato H, Yoiyama K, Ozawa S, Teramachi S, Nakagawa Y, Kido S, Sakata K, Kamiya Y, Itoi T, Hamaoka K, Onouchi Z (1997) Predictors of coronary artery lesions after intravenous gamma-globulin therapy in Kawasaki disease. Prog Med 17:1820-1827
About this article
Cite this article
Sakata, K., Hamaoka, K., Ozawa, S. et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr 166, 565–571 (2007). https://doi.org/10.1007/s00431-006-0280-3
- Discriminate analysis
- Kawasaki disease
- Immune globulin